Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTPW6K5C)

• DOT Name: Mucin-5B (MUC5B)
• Synonyms: MUC-5B; Cervical mucin; High molecular weight salivary mucin MG1; Mucin-5 subtype B, tracheobronchial; Sublingual gland mucin
• Gene Name: MUC5B
• Related Disease:
  Gallbladder carcinoma
  Non-insulin dependent diabetes
  Acute otitis media
  Adenocarcinoma
  Asthma
  Barrett esophagus
  Bladder cancer
  Breast carcinoma
  Breast neoplasm
  Bronchiectasis
  Chronic obstructive pulmonary disease
  Cystic fibrosis
  Dental caries
  Esophageal adenocarcinoma
  Familial adenomatous polyposis
  HIV infectious disease
  Idiopathic interstitial pneumonia
  Inflammatory bowel disease
  Intrahepatic cholangiocarcinoma
  Major depressive disorder
  Malignant tumor of nasopharynx
  Nasal polyp
  Neoplasm
  Pneumocystis pneumonia
  Prostate cancer
  Prostate carcinoma
  Rheumatoid arthritis
  Sjogren syndrome
  Stomach cancer
  Ulcerative colitis
  Urinary bladder cancer
  Urinary bladder neoplasm
  Breast cancer
  Chronic otitis media
  Colorectal carcinoma
  Craniosynostosis
  Influenza
  Lung adenocarcinoma
  Squamous cell carcinoma
  Gallbladder cancer
  Hypersensitivity pneumonitis
  Bacterial infection
  Colon adenocarcinoma
  Crohn disease
  Otitis media
  Pancreatic cancer
  Recessive X-linked ichthyosis
  Respiratory disease
• UniProt ID: MUC5B_HUMAN
• Pfam ID: PF08742 ; PF13330 ; PF01826 ; PF00094
• Sequence:
  MGAPSACRTLVLALAAMLVVPQAETQGPVEPSWENAGHTMDGGAPTSSPTRRVSFVPPVT
  VFPSLSPLNPAHNGRVCSTWGDFHYKTFDGDVFRFPGLCNYVFSEHCRAAYEDFNVQLRR
  GLVGSRPVVTRVVIKAQGLVLEASNGSVLINGQREELPYSRTGLLVEQSGDYIKVSIRLV
  LTFLWNGEDSALLELDPKYANQTCGLCGDFNGLPAFNEFYAHNARLTPLQFGNLQKLDGP
  TEQCPDPLPLPAGNCTDEEGICHRTLLGPAFAECHALVDSTAYLAACAQDLCRCPTCPCA
  TFVEYSRQCAHAGGQPRNWRCPELCPRTCPLNMQHQECGSPCTDTCSNPQRAQLCEDHCV
  DGCFCPPGTVLDDITHSGCLPLGQCPCTHGGRTYSPGTSFNTTCSSCTCSGGLWQCQDLP
  CPGTCSVQGGAHISTYDEKLYDLHGDCSYVLSKKCADSSFTVLAELRKCGLTDNENCLKA
  VTLSLDGGDTAIRVQADGGVFLNSIYTQLPLSAANITLFTPSSFFIVVQTGLGLQLLVQL
  VPLMQVFVRLDPAHQGQMCGLCGNFNQNQADDFTALSGVVEATGAAFANTWKAQAACANA
  RNSFEDPCSLSVENENYARHWCSRLTDPNSAFSRCHSIINPKPFHSNCMFDTCNCERSED
  CLCAALSSYVHACAAKGVQLSDWRDGVCTKYMQNCPKSQRYAYVVDACQPTCRGLSEADV
  TCSVSFVPVDGCTCPAGTFLNDAGACVPAQECPCYAHGTVLAPGEVVHDEGAVCSCTGGK
  LSCLGASLQKSTGCAAPMVYLDCSNSSAGTPGAECLRSCHTLDVGCFSTHCVSGCVCPPG
  LVSDGSGGCIAEEDCPCVHNEATYKPGETIRVDCNTCTCRNRRWECSHRLCLGTCVAYGD
  GHFITFDGDRYSFEGSCEYILAQDYCGDNTTHGTFRIVTENIPCGTTGTTCSKAIKLFVE
  SYELILQEGTFKAVARGPGGDPPYKIRYMGIFLVIETHGMAVSWDRKTSVFIRLHQDYKG
  RVCGLCGNFDDNAINDFATRSRSVVGDALEFGNSWKLSPSCPDALAPKDPCTANPFRKSW
  AQKQCSILHGPTFAACRSQVDSTKYYEACVNDACACDSGGDCECFCTAVAAYAQACHDAG
  LCVSWRTPDTCPLFCDFYNPHGGCEWHYQPCGAPCLKTCRNPSGHCLVDLPGLEGCYPKC
  PPSQPFFNEDQMKCVAQCGCYDKDGNYYDVGARVPTAENCQSCNCTPSGIQCAHSLEACT
  CTYEDRTYSYQDVIYNTTDGLGACLIAICGSNGTIIRKAVACPGTPATTPFTFTTAWVPH
  STTSPALPVSTVCVREVCRWSSWYNGHRPEPGLGGGDFETFENLRQRGYQVCPVLADIEC
  RAAQLPDMPLEELGQQVDCDRMRGLMCANSQQSPPLCHDYELRVLCCEYVPCGPSPAPGT
  SPQPSLSASTEPAVPTPTQTTATEKTTLWVTPSIRSTAALTSQTGSSSGPVTVTPSAPGT
  TTCQPRCQWTEWFDEDYPKSEQLGGDVESYDKIRAAGGHLCQQPKDIECQAESFPNWTLA
  QVGQKVHCDVHFGLVCRNWEQEGVFKMCYNYRIRVLCCSDDHCRGRATTPPPTTELETAT
  TTTTQALFSTPQPTSSPGLTRAPPASTTAVPTLSEGLTSPRYTSTLGTATTGGPTTPAGS
  TEPTVPGVATSTLPTRSALPGTTGSLGTWRPSQPPTLAPTTMATSRARPTGTASTASKEP
  LTTSLAPTLTSELSTSQAETSTPRTETTMSPLTNTTTSQGTTRCQPKCEWTEWFDVDFPT
  SGVAGGDMETFENIRAAGGKMCWAPKSIECRAENYPEVSIDQVGQVLTCSLETGLTCKNE
  DQTGRFNMCFNYNVRVLCCDDYSHCPSTPATSSTATPSSTPGTTWILTKPTTTATTTAST
  GSTATPTSTLRTAPPPKVLTTTATTPTVTSSKATPSSSPGTATALPALRSTATTPTATSV
  TPIPSSSLGTTWTRLSQTTTPTATMSTATPSSTPETAHTSTVLTATATTTGATGSVATPS
  STPGTAHTTKVPTTTTTGFTATPSSSPGTALTPPVWISTTTTPTTRGSTVTPSSIPGTTH
  TATVLTTTTTTVATGSMATPSSSTQTSGTPPSLTTTATTITATGSTTNPSSTPGTTPIPP
  VLTTTATTPAATSNTVTPSSALGTTHTPPVPNTMATTHGRSLPPSSPHTVRTAWTSATSG
  ILGTTHITEPSTVTSHTLAATTGTTQHSTPALSSPHPSSRTTESPPSPGTTTPGHTTATS
  RTTATATPSKTRTSTLLPSSPTSAPITTVVTMGCEPQCAWSEWLDYSYPMPGPSGGDFDT
  YSNIRAAGGAVCEQPLGLECRAQAQPGVPLRELGQVVECSLDFGLVCRNREQVGKFKMCF
  NYEIRVFCCNYGHCPSTPATSSTAMPSSTPGTTWILTELTTTATTTESTGSTATPSSTPG
  TTWILTEPSTTATVTVPTGSTATASSTQATAGTPHVSTTATTPTVTSSKATPFSSPGTAT
  ALPALRSTATTPTATSFTAIPSSSLGTTWTRLSQTTTPTATMSTATPSSTPETVHTSTVL
  TTTATTTGATGSVATPSSTPGTAHTTKVLTTTTTGFTATPSSSPGTARTLPVWISTTTTP
  TTRGSTVTPSSIPGTTHTPTVLTTTTTTVATGSMATPSSSTQTSGTPPSLTTTATTITAT
  GSTTNPSSTPGTTPIPPVLTTTATTPAATSSTVTPSSALGTTHTPPVPNTTATTHGRSLS
  PSSPHTVRTAWTSATSGTLGTTHITEPSTGTSHTPAATTGTTQHSTPALSSPHPSSRTTE
  SPPSPGTTTPGHTRATSRTTATATPSKTRTSTLLPSSPTSAPITTVVTMGCEPQCAWSEW
  LDYSYPMPGPSGGDFDTYSNIRAAGGAVCEQPLGLECRAQAQPGVPLRELGQVVECSLDF
  GLVCRNREQVGKFKMCFNYEIRVFCCNYGHCPSTPATSSTATPSSTPGTTWILTEQTTAA
  TTTATTGSTAIPSSTPGTAPPPKVLTSTATTPTATSSKATSSSSPRTATTLPVLTSTATK
  STATSFTPIPSFTLGTTGTLPEQTTTPMATMSTIHPSSTPETTHTSTVLTTKATTTRATS
  SMSTPSSTPGTTWILTELTTAATTTAATGPTATPSSTPGTTWILTEPSTTATVTVPTGST
  ATASSTRATAGTLKVLTSTATTPTVISSRATPSSSPGTATALPALRSTATTPTATSVTAI
  PSSSLGTAWTRLSQTTTPTATMSTATPSSTPETVHTSTVLTTTTTTTRATGSVATPSSTP
  GTAHTTKVPTTTTTGFTATPSSSPGTALTPPVWISTTTTPTTRGSTVTPSSIPGTTHTAT
  VLTTTTTTVATGSMATPSSSTQTSGTPPSLTTTATTITATGSTTNPSSTPGTTPIPPVLT
  TTATTPAATSSTVTPSSALGTTHTPPVPNTTATTHGRSLPPSSPHTVRTAWTSATSGILG
  TTHITEPSTVTSHTPAATTSTTQHSTPALSSPHPSSRTTESPPSPGTTTPGHTRGTSRTT
  ATATPSKTRTSTLLPSSPTSAPITTVVTTGCEPQCAWSEWLDYSYPMPGPSGGDFDTYSN
  IRAAGGAVCEQPLGLECRAQAQPGVPLRELGQVVECSLDFGLVCRNREQVGKFKMCFNYE
  IRVFCCNYGHCPSTPATSSTATPSSTPGTTWILTKLTTTATTTESTGSTATPSSTPGTTW
  ILTEPSTTATVTVPTGSTATASSTQATAGTPHVSTTATTPTVTSSKATPFSSPGTATALP
  ALRSTATTPTATSFTAIPSSSLGTTWTRLSQTTTPTATMSTATPSSTPETAHTSTVLTTT
  ATTTRATGSVATPSSTPGTAHTTKVPTTTTTGFTVTPSSSPGTARTPPVWISTTTTPTTS
  GSTVTPSSVPGTTHTPTVLTTTTTTVATGSMATPSSSTQTSGTPPSLITTATTITATGST
  TNPSSTPGTTPIPPVLTTTATTPAATSSTVTPSSALGTTHTPPVPNTTATTHGRSLSPSS
  PHTVRTAWTSATSGTLGTTHITEPSTGTSHTPAATTGTTQHSTPALSSPHPSSRTTESPP
  SPGTTTPGHTTATSRTTATATPSKTRTSTLLPSSPTSAPITTVVTTGCEPQCAWSEWLDY
  SYPMPGPSGGDFDTYSNIRAAGGAVCEQPLGLECRAQAQPGVPLGELGQVVECSLDFGLV
  CRNREQVGKFKMCFNYEIRVFCCNYGHCPSTPATSSTAMPSSTPGTTWILTELTTTATTT
  ASTGSTATPSSTPGTAPPPKVLTSPATTPTATSSKATSSSSPRTATTLPVLTSTATKSTA
  TSVTPIPSSTLGTTGTLPEQTTTPVATMSTIHPSSTPETTHTSTVLTTKATTTRATSSTS
  TPSSTPGTTWILTELTTAATTTAATGPTATPSSTPGTTWILTELTTTATTTASTGSTATP
  SSTPGTTWILTEPSTTATVTVPTGSTATASSTQATAGTPHVSTTATTPTVTSSKATPSSS
  PGTATALPALRSTATTPTATSFTAIPSSSLGTTWTRLSQTTTPTATMSTATPSSTPETVH
  TSTVLTATATTTGATGSVATPSSTPGTAHTTKVPTTTTTGFTATPSSSPGTALTPPVWIS
  TTTTPTTTTPTTSGSTVTPSSIPGTTHTARVLTTTTTTVATGSMATPSSSTQTSGTPPSL
  TTTATTITATGSTTNPSSTPGTTPITPVLTSTATTPAATSSKATSSSSPRTATTLPVLTS
  TATKSTATSFTPIPSSTLWTTWTVPAQTTTPMSTMSTIHTSSTPETTHTSTVLTTTATMT
  RATNSTATPSSTLGTTRILTELTTTATTTAATGSTATLSSTPGTTWILTEPSTIATVMVP
  TGSTATASSTLGTAHTPKVVTTMATMPTATASTVPSSSTVGTTRTPAVLPSSLPTFSVST
  VSSSVLTTLRPTGFPSSHFSTPCFCRAFGQFFSPGEVIYNKTDRAGCHFYAVCNQHCDID
  RFQGACPTSPPPVSSAPLSSPSPAPGCDNAIPLRQVNETWTLENCTVARCVGDNRVVLLD
  PKPVANVTCVNKHLPIKVSDPSQPCDFHYECECICSMWGGSHYSTFDGTSYTFRGNCTYV
  LMREIHARFGNLSLYLDNHYCTASATAAAARCPRALSIHYKSMDIVLTVTMVHGKEEGLI
  LFDQIPVSSGFSKNGVLVSVLGTTTMRVDIPALGVSVTFNGQVFQARLPYSLFHNNTEGQ
  CGTCTNNQRDDCLQRDGTTAASCKDMAKTWLVPDSRKDGCWAPTGTPPTASPAAPVSSTP
  TPTPCPPQPLCDLMLSQVFAECHNLVPPGPFFNACISDHCRGRLEVPCQSLEAYAELCRA
  RGVCSDWRGATGGLCDLTCPPTKVYKPCGPIQPATCNSRNQSPQLEGMAEGCFCPEDQIL
  FNAHMGICVQACPCVGPDGFPKFPGERWVSNCQSCVCDEGSVSVQCKPLPCDAQGQPPPC
  NRPGFVTVTRPRAENPCCPETVCVCNTTTCPQSLPVCPPGQESICTQEEGDCCPTFRCRP
  QLCSYNGTFYGVGATFPGALPCHMCTCLSGDTQDPTVQCQEDACNNTTCPQGFEYKRVAG
  QCCGECVQTACLTPDGQPVQLNETWVNSHVDNCTVYLCEAEGGVHLLTPQPASCPDVSSC
  RGSLRKTGCCYSCEEDSCQVRINTTILWHQGCETEVNITFCEGSCPGASKYSAEAQAMQH
  QCTCCQERRVHEETVPLHCPNGSAILHTYTHVDECGCTPFCVPAPMAPPHTRGFPAQEAT
  AV
• Function: Gel-forming mucin that is thought to contribute to the lubricating and viscoelastic properties of whole saliva and cervical mucus.
• Tissue Specificity: Expressed on surface airway epithelia. Expressed mainly in mucous cells of submucosal glands of airway tissues. Highly expressed in the sublingual gland. Also found in submaxillary glands, endocervix, gall bladder, and pancreas.
• KEGG Pathway:
  IL-17 sig.ling pathway (hsa04657)
  Salivary secretion (hsa04970)
• Reactome Pathway:
  Defective C1GALT1C1 causes TNPS (R-HSA-5083632)
  Defective GALNT12 causes CRCS1 (R-HSA-5083636)
  Dectin-2 family (R-HSA-5621480)
  O-linked glycosylation of mucins (R-HSA-913709)
  Termination of O-glycan biosynthesis (R-HSA-977068)
  Defective GALNT3 causes HFTC (R-HSA-5083625)

Molecular Interaction Atlas (MIA) of This DOT

48 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Gallbladder carcinoma	DISD6ACL	Definitive	Biomarker	[1]
Non-insulin dependent diabetes	DISK1O5Z	Definitive	Biomarker	[2]
Acute otitis media	DISL8D8G	Strong	Biomarker	[3]
Adenocarcinoma	DIS3IHTY	Strong	Altered Expression	[4]
Asthma	DISW9QNS	Strong	Biomarker	[5]
Barrett esophagus	DIS416Y7	Strong	Biomarker	[6]
Bladder cancer	DISUHNM0	Strong	Genetic Variation	[7]
Breast carcinoma	DIS2UE88	Strong	Biomarker	[8]
Breast neoplasm	DISNGJLM	Strong	Biomarker	[9]
Bronchiectasis	DIS5MYEE	Strong	Genetic Variation	[10]
Chronic obstructive pulmonary disease	DISQCIRF	Strong	Biomarker	[5]
Cystic fibrosis	DIS2OK1Q	Strong	Altered Expression	[11]
Dental caries	DISRBCMD	Strong	Altered Expression	[12]
Esophageal adenocarcinoma	DISODWFP	Strong	Biomarker	[6]
Familial adenomatous polyposis	DISW53RE	Strong	Biomarker	[13]
HIV infectious disease	DISO97HC	Strong	Altered Expression	[14]
Idiopathic interstitial pneumonia	DISH7LPY	Strong	Biomarker	[15]
Inflammatory bowel disease	DISGN23E	Strong	Biomarker	[16]
Intrahepatic cholangiocarcinoma	DIS6GOC8	Strong	Biomarker	[17]
Major depressive disorder	DIS4CL3X	Strong	Genetic Variation	[18]
Malignant tumor of nasopharynx	DISTGIGF	Strong	Biomarker	[19]
Nasal polyp	DISLP3XE	Strong	Altered Expression	[20]
Neoplasm	DISZKGEW	Strong	Biomarker	[21]
Pneumocystis pneumonia	DISFSOM3	Strong	Biomarker	[22]
Prostate cancer	DISF190Y	Strong	Altered Expression	[23]
Prostate carcinoma	DISMJPLE	Strong	Altered Expression	[23]
Rheumatoid arthritis	DISTSB4J	Strong	Genetic Variation	[24]
Sjogren syndrome	DISUBX7H	Strong	Biomarker	[25]
Stomach cancer	DISKIJSX	Strong	Altered Expression	[26]
Ulcerative colitis	DIS8K27O	Strong	Altered Expression	[27]
Urinary bladder cancer	DISDV4T7	Strong	Genetic Variation	[7]
Urinary bladder neoplasm	DIS7HACE	Strong	Genetic Variation	[7]
Breast cancer	DIS7DPX1	moderate	Biomarker	[8]
Chronic otitis media	DIS3P3TG	moderate	Biomarker	[28]
Colorectal carcinoma	DIS5PYL0	moderate	Genetic Variation	[29]
Craniosynostosis	DIS6J405	moderate	Altered Expression	[30]
Influenza	DIS3PNU3	moderate	Altered Expression	[31]
Lung adenocarcinoma	DISD51WR	moderate	Altered Expression	[32]
Squamous cell carcinoma	DISQVIFL	moderate	Altered Expression	[33]
Gallbladder cancer	DISXJUAF	Disputed	Biomarker	[1]
Hypersensitivity pneumonitis	DIS5IW5K	Disputed	Genetic Variation	[34]
Bacterial infection	DIS5QJ9S	Limited	Biomarker	[35]
Colon adenocarcinoma	DISDRE0J	Limited	Altered Expression	[36]
Crohn disease	DIS2C5Q8	Limited	Altered Expression	[37]
Otitis media	DISGZDUO	Limited	Biomarker	[38]
Pancreatic cancer	DISJC981	Limited	Altered Expression	[39]
Recessive X-linked ichthyosis	DISZY56W	Limited	Biomarker	[40]
Respiratory disease	DISGGAGJ	Limited	Altered Expression	[41]

3 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the methylation of Mucin-5B (MUC5B).	[42]
Fulvestrant	DM0YZC6	Approved	Fulvestrant increases the methylation of Mucin-5B (MUC5B).	[45]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the methylation of Mucin-5B (MUC5B).	[47]

5 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Estradiol	DMUNTE3	Approved	Estradiol increases the expression of Mucin-5B (MUC5B).	[43]
Progesterone	DMUY35B	Approved	Progesterone increases the expression of Mucin-5B (MUC5B).	[44]
(+)-JQ1	DM1CZSJ	Phase 1	(+)-JQ1 decreases the expression of Mucin-5B (MUC5B).	[48]
Leflunomide	DMR8ONJ	Phase 1 Trial	Leflunomide increases the expression of Mucin-5B (MUC5B).	[49]
PMID28870136-Compound-48	DMPIM9L	Patented	PMID28870136-Compound-48 decreases the expression of Mucin-5B (MUC5B).	[50]

1 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Capsaicin	DMGMF6V	Approved	Capsaicin increases the secretion of Mucin-5B (MUC5B).	[46]

References

• [1] Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma.Histopathology. 2019 Mar;74(4):597-607. doi: 10.1111/his.13797. Epub 2019 Jan 28.
• [2] Common and rare exonic MUC5B variants associated with type 2 diabetes in Han Chinese.PLoS One. 2017 Mar 27;12(3):e0173784. doi: 10.1371/journal.pone.0173784. eCollection 2017.
• [3] Relationship of the Middle Ear Effusion Microbiome to Secretory Mucin Production in Pediatric Patients With Chronic Otitis Media.Pediatr Infect Dis J. 2017 Jul;36(7):635-640. doi: 10.1097/INF.0000000000001493.
• [4] FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas.PLoS Genet. 2017 Dec 21;13(12):e1007097. doi: 10.1371/journal.pgen.1007097. eCollection 2017 Dec.
• [5] The C-terminal dimerization domain of the respiratory mucin MUC5B functions in mucin stability and intracellular packaging before secretion.J Biol Chem. 2019 Nov 8;294(45):17105-17116. doi: 10.1074/jbc.RA119.010771. Epub 2019 Sep 30.
• [6] Elucidation of the AGR2 Interactome in Esophageal Adenocarcinoma Cells Identifies a Redox-Sensitive Chaperone Hub for the Quality Control of MUC-5AC.Antioxid Redox Signal. 2019 Nov 20;31(15):1117-1132. doi: 10.1089/ars.2018.7647. Epub 2019 Sep 25.
• [7] Variants of MUC5B minisatellites and the susceptibility of bladder cancer.DNA Cell Biol. 2009 Apr;28(4):169-76. doi: 10.1089/dna.2008.0827.
• [8] MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells.Int J Oncol. 2016 May;48(5):2113-23. doi: 10.3892/ijo.2016.3434. Epub 2016 Mar 10.
• [9] Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues.J Histochem Cytochem. 2006 Mar;54(3):289-99. doi: 10.1369/jhc.5A6763.2005. Epub 2005 Sep 7.
• [10] Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis.Am J Respir Crit Care Med. 2020 Mar 15;201(6):661-670. doi: 10.1164/rccm.201906-1219OC.
• [11] IL-1 dominates the promucin secretory cytokine profile in cystic fibrosis.J Clin Invest. 2019 Oct 1;129(10):4433-4450. doi: 10.1172/JCI125669.
• [12] MUC7 Level As A New Saliva Risk Factor For Dental Caries In Adult Patients.Int J Med Sci. 2019 Jan 1;16(2):241-246. doi: 10.7150/ijms.29027. eCollection 2019.
• [13] Oncocytic papillary neoplasms of the biliary tract: a clinicopathological, mucin core and Wnt pathway protein analysis of four cases.Pathology. 2007 Aug;39(4):413-8. doi: 10.1080/00313020701444531.
• [14] Quantitative analysis of differentially expressed saliva proteins in human immunodeficiency virus type 1 (HIV-1) infected individuals.Anal Chim Acta. 2013 Apr 24;774:61-6. doi: 10.1016/j.aca.2013.02.038. Epub 2013 Mar 1.
• [15] Unique expression profiles of mucin proteins in interstitial pneumonia-associated lung adenocarcinomas.Histol Histopathol. 2019 Nov;34(11):1243-1254. doi: 10.14670/HH-18-114. Epub 2019 Apr 9.
• [16] IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77.
• [17] Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.Virchows Arch. 2017 May;470(5):537-543. doi: 10.1007/s00428-017-2114-2. Epub 2017 Mar 29.
• [18] The PHF21B gene is associated with major depression and modulates the stress response.Mol Psychiatry. 2017 Jul;22(7):1015-1025. doi: 10.1038/mp.2016.174. Epub 2016 Oct 25.
• [19] HSP70 and mucin 5B: novel protein targets of N,N'-dinitrosopiperazine-induced nasopharyngeal tumorigenesis.Cancer Sci. 2009 Feb;100(2):216-24. doi: 10.1111/j.1349-7006.2008.01028.x.
• [20] Distinct expression of NK2 homeobox 1 (NKX2-1) and goblet cell hyperplasia in nasal polyps with different endotypes.Int Forum Allergy Rhinol. 2017 Jul;7(7):690-698. doi: 10.1002/alr.21932. Epub 2017 Mar 20.
• [21] Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids.Ann Transl Med. 2018 Sep;6(17):333. doi: 10.21037/atm.2018.07.16.
• [22] Increase in secreted airway mucins and partial Muc5b STAT6/FoxA2 regulation during Pneumocystis primary infection.Sci Rep. 2019 Feb 14;9(1):2078. doi: 10.1038/s41598-019-39079-4.
• [23] Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft.Br J Cancer. 2004 Feb 9;90(3):720-7. doi: 10.1038/sj.bjc.6601570.
• [24] New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern?.Curr Opin Pulm Med. 2019 Sep;25(5):442-449. doi: 10.1097/MCP.0000000000000600.
• [25] Reduced sulfation of muc5b is linked to xerostomia in patients with Sjgren syndrome.Ann Rheum Dis. 2008 Oct;67(10):1480-7. doi: 10.1136/ard.2007.078246. Epub 2007 Nov 12.
• [26] Aberrant expression of human mucin gene MUC5B in gastric carcinoma and cancer cells. Identification and regulation of a distal promoter.J Biol Chem. 2001 May 4;276(18):15386-96. doi: 10.1074/jbc.M010534200. Epub 2001 Jan 30.
• [27] Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis.J Histochem Cytochem. 2006 Dec;54(12):1335-48. doi: 10.1369/jhc.5A6904.2006. Epub 2006 Aug 21.
• [28] Characterization of mucins in human middle ear and Eustachian tube.Am J Physiol Lung Cell Mol Physiol. 2001 Jun;280(6):L1157-67. doi: 10.1152/ajplung.2001.280.6.L1157.
• [29] Recurrent, low-frequency coding variants contributing to colorectal cancer in the Swedish population.PLoS One. 2018 Mar 16;13(3):e0193547. doi: 10.1371/journal.pone.0193547. eCollection 2018.
• [30] MUC5B secretion is up-regulated in sinusitis compared with controls.Am J Rhinol. 2006 Sep-Oct;20(5):554-7. doi: 10.2500/ajr.2006.20.2935.
• [31] Combined treatment with SB203580 and dexamethasone suppresses non-typeable Haemophilus influenzae-induced Th17 inflammation response in murine allergic asthma.Eur J Pharmacol. 2019 Nov 5;862:172623. doi: 10.1016/j.ejphar.2019.172623. Epub 2019 Aug 22.
• [32] Long non-coding RNA MUC5B-AS1 promotes metastasis through mutually regulating MUC5B expression in lung adenocarcinoma.Cell Death Dis. 2018 May 1;9(5):450. doi: 10.1038/s41419-018-0472-6.
• [33] Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer.Sci Rep. 2015 Mar 3;5:8649. doi: 10.1038/srep08649.
• [34] Integrating Genomics Into Management ofFibrotic Interstitial Lung Disease.Chest. 2019 May;155(5):1026-1040. doi: 10.1016/j.chest.2018.12.011. Epub 2019 Jan 17.
• [35] Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction.Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Feb;1865(2):158538. doi: 10.1016/j.bbalip.2019.158538. Epub 2019 Oct 31.
• [36] Quantitation of mucin mRNA in respiratory and intestinal epithelial cells.Am J Respir Cell Mol Biol. 1994 Dec;11(6):742-50. doi: 10.1165/ajrcmb.11.6.7946402.
• [37] Abnormalities in mucin gene expression in Crohn's disease.Inflamm Bowel Dis. 1999 Feb;5(1):24-32. doi: 10.1097/00054725-199902000-00004.
• [38] Mucin gene polymorphisms in otitis media patients.Laryngoscope. 2010 Jan;120(1):132-8. doi: 10.1002/lary.20688.
• [39] DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.Tumour Biol. 2016 Sep;37(9):12193-12202. doi: 10.1007/s13277-016-5079-x. Epub 2016 May 26.
• [40] Atypical X-linked ichthyosis in a patient with a large deletion involving the steroid sulfatase (STS) gene.Int J Dermatol. 2009 Feb;48(2):142-4. doi: 10.1111/j.1365-4632.2009.03996.x.
• [41] Role of Spdef in the Regulation of Muc5b Expression in the Airways of Naive and Mucoobstructed Mice.Am J Respir Cell Mol Biol. 2018 Sep;59(3):383-396. doi: 10.1165/rcmb.2017-0127OC.
• [42] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [43] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [44] Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
• [45] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [46] TRPV1 and TRPA1 stimulation induces MUC5B secretion in the human nasal airway in vivo. Clin Physiol Funct Imaging. 2011 Nov;31(6):435-44. doi: 10.1111/j.1475-097X.2011.01039.x. Epub 2011 Jul 26.
• [47] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [48] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [49] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [50] Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. Respir Res. 2005 Aug 8;6(1):89. doi: 10.1186/1465-9921-6-89.